Q BioMed (Q BioMed) 3-Year Dividend Growth Rate : 0.00% (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed 3-Year Dividend Growth Rate?

Q BioMed's Dividends per Share for the three months ended in Feb. 2023 was $0.00.

The historical rank and industry rank for Q BioMed's 3-Year Dividend Growth Rate or its related term are showing as below:

QBIO's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Q BioMed's Dividend Payout Ratio for the three months ended in Feb. 2023 was 0.00. As of today, Q BioMed's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Q BioMed's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Q BioMed's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Q BioMed's 3-Year Dividend Growth Rate falls into.

Q BioMed 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Q BioMed (OTCPK:QBIO) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Q BioMed's Dividend Payout Ratio for the quarter that ended in Feb. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Feb. 2023 )	/	EPS without NRI (Q: Feb. 2023 )
	=	0	/	-0.02
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q BioMed 3-Year Dividend Growth Rate Related Terms>

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1